Research: ACMD review of the evidence on the use and harms of Cumyl-PeGaClone

⌂Back To Homepage Subscribe To RSS Feed

Advisory Council On The Misuse Of Drugs

June 8

10:08 2023

Print This Article Share it With Friends

Created by Advisory Council On The Misuse Of Drugs 0 comments

ACMD review of the evidence on the use and harms of Cumyl-PeGaClone

PDF, 444 KB, 35 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter from ACMD to the Home Secretary: ACMD review of Cumyl-PeGaClone (accessible)

HTML

Letter from ACMD to the Home Secretary: ACMD review of Cumyl-PeGaClone

PDF, 143 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

Details

In 2022 the Advisory Council on the Misuse of Drugs (ACMD) was commissioned to give advice on the appropriate classification and scheduling of the synthetic cannabinoid receptor agonist (SCRA) Cumyl-PeGaClone under the Misuse of Drugs Act 1971. Cumyl-PeGaClone was added to schedule II of the Convention on Psychotropic Substances of 1971 during the 64th Commission on Narcotic Drugs (CND) meeting in April 2021.

The ACMD has therefore written this report describing the use and harms of Cumyl-PeGaClone and other recently encountered SCRA and has provided recommendations on their classification and scheduling.

We are aware this publication may have accessibility issues. We are reviewing it so that we can fix these. Read more about our accessible documents policy.

Published 25 May 2023
Last updated 8 June 2023 +show all updates